IGB specifications

Information


Unique identifier OMICS_22784
Name Individualized Genetic Barrier
Software type Package/Module
Interface Command line interface
Restrictions to use None
Operating system Unix/Linux, Mac OS, Windows
Programming languages R
License GNU General Public License version 2.0
Computer skills Advanced
Stability Stable
Maintained Yes

Download


Versioning


Add your version

Maintainer


  • person_outline Niko Beerenwinkel <>

IGB article

IGB institution(s)
Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland; SIB Swiss Institute of Bioinformatics, Basel, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; Clinic for Infectious Diseases, Bern University Hospital, Bern, Switzerland; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland; Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland; Division of Infectious Diseases, University Hospital Lausanne, Lausanne, Switzerland; Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland; Division of Infectious Diseases, Regional Hospital Lugano, Lugano, Switzerland; Laboratory of Virology, University Hospital Geneva, Geneva, Switzerland; Swiss National Center for Retroviruses, Institute of Medical Virology, University of Zurich, Zurich, Switzerland; Institute for Medical Microbiology, University of Basel, Basel, Switzerland; Division of Immunology and Allergy, Centre Hospitalier Universitaire Vadois, Lausanne, Switzerland
IGB funding source(s)
Supported by the Swiss HIV Cohort Study [grant numbers 470, 528, 569, 629]; the Swiss HIV Cohort Study Research Foundation; the Swiss National Science Foundation [grant numbers 33CS30-134277, 3247B0-112594 and, 324730-130865, CR32I2_127017]; the Collaborative HIV and Anti-HIV Drug Resistance Network [grant number 223131] of the European Community’s Seventh Framework Programme [grant number FP7/2007-2013]; a research grant of the Union Bank of Switzerland, in the name of a donor; an unrestricted research grant from Gilead, Switzerland to the SHCS Research Foundation and by the University of Zurich’s Clinical Research Priority Program (CRPP) ‘‘Viral infectious diseases: Zurich Primary HIV Infection Study’’.

IGB reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review IGB

Related Tools